Insurance Coverage Guide ·
By The RX Index Editorial Team · · Updated monthly or when DHA/Express Scripts publishes changes
Does TRICARE Cover GLP-1?
What’s covered for Wegovy, Ozempic, Zepbound, and Mounjaro in 2026 — plus the exact prior-authorization rules that cause most denials.
Does TRICARE cover GLP-1? Yes — but the answer splits three ways depending on which drug, which diagnosis, and which TRICARE plan. TRICARE covers Ozempic, Mounjaro, Trulicity, and Victoza for type 2 diabetes with prior authorization. It covers Wegovy, Zepbound, and Saxenda for weight management — but only for Prime, Select, and certain premium-based plans, and only after meeting strict clinical criteria. The biggest catch: TRICARE For Life lost weight-loss GLP-1 coverage on August 31, 2025, and asking for Ozempic or Mounjaro when you actually need the weight-loss path is one of the most common reasons people get denied.
Below is the coverage breakdown assembled from current official TRICARE, Express Scripts, and DHA source documents — reconciled into one place so you don’t have to bounce between five government websites to figure out what applies to you.
Quick Coverage Lookup
| Your Situation | Weight-Loss GLP-1 (Wegovy, Zepbound) | Diabetes GLP-1 (Ozempic, Mounjaro) | Next Step |
|---|---|---|---|
| Prime / Prime Remote — Active Duty | ✅ Covered, $0 copay | ✅ Covered, $0 copay | Talk to your PCM; service-specific weight-management program rules may apply |
| Prime / Select — Dependents & Retirees | ✅ Covered with PA + step therapy | ✅ Covered with PA | Use the pre-visit checklist below ↓ |
| Reserve Select, Young Adult, Retired Reserve, CHCBP | ✅ Covered with PA + step therapy | ✅ Covered with PA | Same PA path as Prime/Select dependents |
| TRICARE For Life | ❌ Not covered since Aug 31, 2025 | ✅ Covered for T2D with PA | See options if excluded below ↓ |
| US Family Health Plan | ⚠️ Uses its own pharmacy plan — verify directly | ⚠️ Uses its own pharmacy plan — verify directly | Call your USFHP site before proceeding |
| Direct Care Only | ❌ Not eligible for weight-loss drug coverage | ❌ Pharmacy coverage limited — see note | Talk to your MTF about available options |
Sources: Express Scripts TRICARE Pharmacy FAQ, TRICARE.mil coverage explainer (Aug 2025), DHA Newsroom Q&A (Sept 2025), TRICARE Prior Authorization Newsroom article.
TRICARE does not make this easy. The rules are spread across multiple agencies, multiple forms, and multiple plan types — and the prior authorization process has specific documentation requirements that trip up even providers who think they know the system. But the rules are specific enough that if you match the right drug to the right diagnosis and bring the right paperwork, you can navigate around the vague “TRICARE won’t cover it” dead end that stops most people.
Does TRICARE Cover GLP-1?
Yes — but not every GLP-1, not for every diagnosis, and not under every plan. TRICARE splits GLP-1 coverage into two completely separate tracks: diabetes and weight management. Using the wrong track is the fastest way to get denied.
The key distinction: drugs like Ozempic and Mounjaro are only covered for type 2 diabetes. For weight management, the covered drugs are Wegovy, Zepbound, and Saxenda — each with their own prior authorization criteria. The rest of this guide breaks down exactly what’s required for each path.
Which GLP-1 Drugs Does TRICARE Cover Right Now?
TRICARE’s public guidance from Express Scripts and TRICARE.mil lists specific GLP-1 medications under each track. Here’s the current drug-by-drug breakdown as of April 2026.
The RX Index TRICARE GLP-1 Drug Coverage Matrix
| Drug | Covered For | Plan Restriction | Prior Auth? | Extra Paperwork | Biggest Denial Risk |
|---|---|---|---|---|---|
| Wegovy (semaglutide) | Weight management | Prime/Select/premium-based only | Yes + step therapy | Weight-loss PA form (March 12, 2026 version) | Missing step-drug trial or lifestyle documentation |
| Zepbound (tirzepatide) | Weight management + Obstructive Sleep Apnea | Prime/Select/premium-based only | Yes + step therapy (weight); Yes (OSA) | Weight-loss PA form (March 12, 2026 version) | Same as Wegovy; OSA path requires AHI ≥15 |
| Saxenda (liraglutide) | Weight management | Prime/Select/premium-based only | Yes | [NEEDS VERIFICATION — current live tier/form not confirmed from public documents] | Verify current PA requirements before submitting |
| Ozempic (semaglutide) | Type 2 diabetes ONLY | All plans using TRICARE Pharmacy Program | Yes + medical necessity form | Diabetes PA form + medical necessity form | Being prescribed for weight loss, not diabetes |
| Mounjaro (tirzepatide) | Type 2 diabetes ONLY | All plans using TRICARE Pharmacy Program | Yes + medical necessity form | Diabetes PA form + medical necessity form | Being prescribed for weight loss, not diabetes |
| Trulicity (dulaglutide) | Type 2 diabetes | All plans using TRICARE Pharmacy Program | Yes | Diabetes PA form (lower copay tier — often the formulary step comparator) | May be required before Ozempic/Mounjaro |
| Victoza (liraglutide) | Type 2 diabetes | All plans using TRICARE Pharmacy Program | Yes + medical necessity form | Diabetes PA form + medical necessity form | Similar to Ozempic/Mounjaro |
| Foundayo (orforglipron) | Not confirmed on TRICARE formulary | N/A | N/A | N/A | FDA approved April 1, 2026 — awaiting DoD P&T review |
Sources: Express Scripts TRICARE GLP-1 FAQ, TRICARE.mil Wegovy/Ozempic/Mounjaro FAQ, DHA coverage explainer, March 12, 2026 weight-loss PA form accessed via the TRICARE Formulary Search Tool. Saxenda live formulary status marked [NEEDS VERIFICATION]. Foundayo TRICARE formulary status not confirmed from public-facing documents as of April 15, 2026.
What We Verified for This Table
We checked the current Express Scripts TRICARE pharmacy FAQ page, the official TRICARE.mil Wegovy/Ozempic/Mounjaro coverage FAQ, and the live prior authorization forms accessible through the TRICARE Formulary Search Tool. The weight-loss PA form we reviewed is dated . We could not independently verify Saxenda’s current standalone form or exact formulary tier from public-facing documents, so it’s flagged. Foundayo’s TRICARE formulary status is pending — the DoD Pharmacy & Therapeutics Committee reviews the formulary quarterly, and no public announcement has been made as of .
Which TRICARE Plans Still Cover Weight-Loss GLP-1 Medications?
Weight-loss GLP-1 access is now gated almost entirely by plan type. This is the part of the rules that changed in 2025 and continues to cause the most confusion.
Plans That Cover GLP-1s for Weight Loss
The Defense Health Agency’s public coverage materials list these plans as eligible for weight-loss medication coverage when clinical criteria are met:
- ✅TRICARE Prime (active duty, dependents, retirees)
- ✅TRICARE Prime Remote and Prime Overseas / Prime Remote Overseas
- ✅TRICARE Select and Select Overseas
- ✅TRICARE Young Adult (Prime and Select options)
- ✅TRICARE Reserve Select
- ✅TRICARE Retired Reserve
- ✅Continued Health Care Benefit Program (CHCBP)
The prescription must come from a TRICARE-authorized or network provider (including MTF providers), and prior authorization must be approved by Express Scripts.
Plans Excluded from Weight-Loss GLP-1 Coverage
- ❌TRICARE For Life (TFL) — Weight-loss GLP-1 coverage ended . All existing prior authorizations for weight-loss medications were immediately invalidated. No grandfathering. GLP-1s for type 2 diabetes remain covered for TFL beneficiaries with prior authorization.
- ❌Direct care only beneficiaries
- ❌Foreign force members
- ❌TRICARE Plus
The DHA’s official position: federal law and regulation (32 CFR §199.17(f)(3)) do not authorize TFL to cover weight-loss medications when obesity is the sole or major condition treated.
TRICARE For Life: What Actually Happened
On , the Defense Health Agency implemented what it called “existing regulatory controls” that ended weight-loss medication coverage for TFL beneficiaries. The move affected Wegovy, Zepbound, Saxenda, Qsymia, Phentermine, and Contrave when prescribed for weight loss.
The Military Officers Association of America (MOAA) has challenged this decision on multiple fronts, arguing it creates two classes of drug coverage — one for TRICARE, one for TRICARE For Life — which MOAA believes violates Congressional intent for a uniform pharmacy benefit across all TRICARE categories.
A legal challenge filed by Col. Derence Fivehouse, USAF (Ret), made national headlines in — not for the merits of the case, but because a Department of Justice lawyer assigned to defend the policy was fired after submitting AI-generated court filings containing fabricated quotations. The underlying case — challenging the DHA’s authority to create a two-tier coverage system — remains pending as of .
The honest reality for TFL beneficiaries
There is no indication this policy will be reversed in the near term. If you’re on TRICARE For Life and want GLP-1 medication for weight management, planning for an out-of-pocket path is more practical right now than waiting for the legal or legislative process to play out. See cash-pay options below →
The US Family Health Plan Warning
This is a detail almost every other guide gets wrong — or ignores entirely.
The DHA’s public coverage flyer groups US Family Health Plan (USFHP) under Prime-eligible plans. But a separate official TRICARE prior-authorization article states that USFHP does not have coverage through the TRICARE Pharmacy Program and has its own pharmacy plan. That’s a direct contradiction in official materials.
If you have USFHP, do not assume the coverage rules in this guide apply to you. Call your specific USFHP site directly to confirm GLP-1 coverage, formulary status, and prior authorization requirements before your doctor submits anything.
Does TRICARE Cover Wegovy or Zepbound for Weight Loss?
Yes — for eligible plans (Prime, Select, and premium-based plans), TRICARE covers both Wegovy and Zepbound for chronic weight management. But approval requires meeting every criterion on the current prior authorization form, and the requirements are more specific than most people expect.
We reviewed the weight-loss PA form available through the TRICARE Formulary Search Tool. Here’s exactly what it requires:
Adult Weight-Management Path (Wegovy and Zepbound)
| Requirement | What the March 12, 2026 Form Says | Common Mistake |
|---|---|---|
| BMI | ≥30, or ≥27 with at least one qualifying comorbidity | BMI not documented recently enough in medical records |
| Qualifying comorbidities (if BMI 27–29) | Diabetes or impaired glucose tolerance, obstructive sleep apnea, osteoarthritis, metabolic syndrome, dyslipidemia, hypertension, metabolic dysfunction-associated steatohepatitis (MASH), or established cardiovascular disease (prior stroke, MI, or peripheral artery disease) | Assuming any health condition counts — the form lists specific conditions |
| Lifestyle modification | 6+ months of documented behavioral modification AND dietary restriction | Not in medical records, or documented for less than 6 months |
| Step therapy | Must try for at least 3 months and fail — or have a documented contraindication or adverse reaction to — generic phentermine, benzphetamine, diethylpropion (IR or SR), or phendimetrazine (IR or SR) | This is the requirement that trips up the most people. Many providers assume the step drugs are Contrave, Qsymia, or Saxenda — those are not what the current TRICARE form requires. |
| Ongoing commitment | Must remain engaged in behavioral modification and a reduced-calorie diet during therapy | Rarely the reason for initial denial, but documented at renewal |
| Prescriber | Must be an MTF provider or TRICARE-authorized network provider who has billed TRICARE for the assessment and/or treatment planning | Using a provider outside the TRICARE network |
| Renewal | Must demonstrate at least 5% baseline body weight loss at annual renewal | Not tracking or documenting weight change |
The Step-Therapy Detail That Causes the Most Confusion
The March 12, 2026 weight-loss PA form requires a trial of specific generic sympathomimetic amine appetite suppressants — phentermine, benzphetamine, diethylpropion, or phendimetrazine — for at least 3 months. It does not require Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate combination), or Saxenda (liraglutide) as step drugs.
This matters because many online guides — and some providers — still reference the older step-drug list. If your provider documents a trial of Contrave or Qsymia but doesn’t document a trial of generic phentermine or one of the other agents specifically listed on the current form, the PA may be denied even though you technically tried a weight-loss medication. Bring this detail to your appointment.
Initial Approval and Renewal Timeline
Initial approval is valid for 12 months. Annual renewal is required, and the renewal criteria include documented weight loss of at least 5% from baseline for adults. If you start at 250 lbs, you need to show at least 12.5 lbs lost by your first renewal — in documented medical records, not verbal report.
Does TRICARE Cover Zepbound for Sleep Apnea?
Yes — and this is a pathway most guides completely miss.
The March 12, 2026 PA form includes a distinct adult obstructive sleep apnea (OSA) path that is available for Zepbound only (not Wegovy). This matters because the OSA path has different criteria than the standard weight-management path, and it may apply to readers who don’t meet the weight-loss step-therapy requirements but do have diagnosed sleep apnea.
Zepbound OSA Path Requirements
- •Age 18+
- •BMI ≥30
- •Apnea-Hypopnea Index (AHI) ≥15 (moderate-to-severe OSA)
- •6 months of documented behavioral modification
- •Renewal based on improvement in OSA symptoms and/or AHI
This pathway is Zepbound-specific. Wegovy does not have an FDA-approved OSA indication, so it cannot be prescribed through this route.
Does TRICARE Cover Wegovy for Teens?
Yes, with limits. The March 12, 2026 PA form allows Wegovy injection (not Wegovy tablets) for ages 12–17 on a pediatric weight-management path. Zepbound is not listed for this pediatric route on the current form.
Does TRICARE Cover Ozempic or Mounjaro for Weight Loss?
No. This is the question that generates the most confusion — and the most unnecessary denials.
TRICARE covers Ozempic and Mounjaro for type 2 diabetes only. The current diabetes prior-authorization form explicitly blocks coverage when these drugs are being prescribed for weight loss. If your provider submits a PA for Ozempic or Mounjaro citing weight management as the reason, it will be denied.
Here’s what makes this confusing: Ozempic and Wegovy contain the same active ingredient (semaglutide). Mounjaro and Zepbound contain the same active ingredient (tirzepatide). But they are different products with different FDA approvals and different TRICARE coverage paths.
Want weight loss? Ask for Wegovy or Zepbound
Have type 2 diabetes? Ozempic, Mounjaro, Trulicity, or Victoza may be covered
Want weight loss but asked for Ozempic? Will be denied
Additionally, Ozempic, Mounjaro, and Victoza each require a medical necessity form (separate from the PA form) to get formulary copay rates or to fill at a military pharmacy. Trulicity sits on a lower copay tier and is often the formulary step comparator in the diabetes PA logic.
The Diabetes PA Path (Brief Overview)
For readers pursuing the diabetes GLP-1 path, the current diabetes PA form has its own step logic. The general sequence involves: documented type 2 diabetes diagnosis → metformin trial (or contraindication/intolerance) → consideration of Bydureon BCise or renal-limitation documentation → Trulicity trial or documentation of why it’s not appropriate → before Ozempic or Mounjaro can be approved. Confirm specific requirements using the TRICARE Formulary Search Tool, which links to the current diabetes PA form.
What Does TRICARE Prior Authorization Require?
Prior authorization is where the real decision happens. TRICARE’s public guidance says the traditional PA process takes approximately 10 business days after Express Scripts receives the completed request from your provider.
How to Check Coverage Before Starting
Use the TRICARE Formulary Search Tool at militaryrx.express-scripts.com. Enter the drug name and your information. The tool will show: whether the drug is on the formulary and its tier, which pharmacy channels it can be filled through, whether PA and/or medical necessity forms are required, and links to download the actual PA forms.
Weight-Loss Track (Wegovy, Zepbound, Saxenda)
PA form with BMI, comorbidity, lifestyle documentation, step-therapy documentation (3 months of generic phentermine or related agents), and network prescriber requirements. Detailed above.
Diabetes Track (Ozempic, Mounjaro, Trulicity, Victoza)
Separate PA form with its own step logic, plus medical necessity form for some drugs. Requires documented type 2 diabetes diagnosis. Explicitly blocks weight-loss use.
How Much Do Covered GLP-1 Medications Cost Under TRICARE?
There’s no universal GLP-1 copay — it depends on your beneficiary category, where you fill the prescription, and the drug’s formulary status. Here are the verified 2026 rates for most beneficiaries.
2026 TRICARE Pharmacy Copays — Most Beneficiaries
| Pharmacy Channel | Generic Formulary | Brand-Name Formulary | Non-Formulary |
|---|---|---|---|
| Military Pharmacy (up to 90-day supply) | $0 | $0 | Generally not available without approved medical necessity |
| TRICARE Home Delivery (up to 90-day supply) | $14 | $44 | $85 |
| Network Retail Pharmacy (up to 30-day supply) | $16 | $48 | $85 |
| Non-Network Pharmacy — Prime (up to 30-day supply) | 50% cost-share after POS deductible | 50% cost-share after POS deductible | 50% cost-share after POS deductible |
| Non-Network Pharmacy — All Other Plans (up to 30-day supply) | $48 or 20%, whichever is greater, after annual deductible | $48 or 20%, whichever is greater, after annual deductible | $85 or 20%, whichever is greater, after annual deductible |
Active-duty servicemembers: $0 for covered drugs at military pharmacies, TRICARE Home Delivery, and network retail pharmacies.
Active-duty family members with TRICARE Prime Remote (U.S.): As of , $0 for covered drugs at Home Delivery and network retail pharmacies.
Survivors of active-duty servicemembers and medically retired servicemembers: Copayments frozen at previous rates — no increase in 2026.
All other beneficiaries: Pay the rates listed in the table above.
What This Means for GLP-1 Specifically
Your lowest-cost option is always a military pharmacy ($0 for formulary drugs) if it stocks the medication. Second-best is TRICARE Home Delivery — at $44 for a 90-day brand-name formulary supply, that works out to roughly $15/month, which is among the cheapest GLP-1 access points in the country. Always check the live Formulary Search Tool for per-drug copay rates — TRICARE updates formulary classifications quarterly.
Source: TRICARE.mil/Costs/PharmacyCosts (2026–2027 rates), Express Scripts 2026 copay announcement, Military.com (April 2026). Effective through .
Why Do People Get Denied — Even When They Think They Qualify?
Most TRICARE GLP-1 denials aren’t random. After reviewing the PA form requirements, official guidance, and public beneficiary reports, the same patterns come up repeatedly.
Wrong drug for the intent
The provider requested Ozempic or Mounjaro for a patient who wants weight loss — not diabetes management. The diabetes PA form explicitly blocks this. The fix: ask for Wegovy or Zepbound instead.
Wrong step-therapy drugs documented
The weight-loss PA form requires a 3-month trial of generic phentermine, benzphetamine, diethylpropion, or phendimetrazine — or documented contraindication. If your records show Contrave or Qsymia but not one of the agents on the current form, the PA can be denied. This is the fix that unlocks the most stuck applications.
Insufficient lifestyle modification documentation
The form requires 6 months of documented behavioral modification and dietary restriction. "I've been dieting for years" doesn't count unless it's in your medical records. The provider needs chart notes showing this.
Wrong plan assumption
The patient is on TRICARE For Life and either didn't know or wasn't told that TFL weight-loss coverage ended August 31, 2025. No amount of documentation fixes a plan exclusion.
Non-network prescriber
The PA form requires the prescriber to be an MTF provider or TRICARE-authorized network provider who has billed TRICARE for assessment and/or treatment planning. A prescriber outside the TRICARE network generally cannot submit these PAs.
Denial Quick-Fix Table
| Denial Reason | What's Missing | Where It Appears on the PA Form | Fastest Fix |
|---|---|---|---|
| Wrong drug (Ozempic for weight loss) | Wrong PA track entirely | Diabetes form blocks weight-loss use | Resubmit with Wegovy or Zepbound on weight-loss form |
| Step therapy not met | 3-month trial of listed generic agents | Weight-loss form, step-therapy section | Document trial of generic phentermine (or listed alternative), or document contraindication |
| Lifestyle modification insufficient | 6 months of behavioral/dietary records | Weight-loss form, lifestyle section | Have provider add chart notes for prior 6 months, then resubmit |
| BMI not documented | Recent BMI measurement | Weight-loss form, BMI section | Document current BMI at next visit, then resubmit |
| Non-network prescriber | TRICARE-billed provider relationship | Weight-loss form, prescriber section | Transfer care to MTF or TRICARE network provider |
| Plan exclusion (TFL) | Eligible plan enrollment | Not fixable through PA | Explore cash-pay alternatives or covered non-GLP-1 options |
What Should You Bring Before Your Doctor Submits the Request?
Instead of a vague “talk to your provider,” here’s the specific documentation you need assembled before that appointment — so your provider can submit a clean PA the first time.
The RX Index TRICARE GLP-1 Pre-Visit Checklist
Before the visit, confirm:
- Your TRICARE plan type — Prime, Prime Remote, Select, Reserve Select, Young Adult, Retired Reserve, or CHCBP. If you have TFL, USFHP, or direct care only, verify coverage separately before proceeding.
- Your provider is TRICARE-authorized/network and has billed TRICARE — MTF providers qualify. Verify civilian providers are in the TRICARE network.
- Your current BMI — must be ≥30, or ≥27 with at least one qualifying comorbidity documented in your medical records.
Documentation to bring or confirm is in your chart:
- Qualifying comorbidity (if BMI 27-29): Documented diagnosis of diabetes or impaired glucose tolerance, obstructive sleep apnea, osteoarthritis, metabolic syndrome, dyslipidemia, hypertension, metabolic dysfunction-associated steatohepatitis (MASH), or established cardiovascular disease.
- 6+ months of lifestyle modification: Chart notes showing behavioral modification and dietary restriction attempts. If this isn't documented yet, discuss with your provider how to build this record.
- Step-therapy history: Documentation of at least a 3-month trial — or documented contraindication/adverse reaction — of generic phentermine, benzphetamine, diethylpropion (IR or SR), or phendimetrazine (IR or SR). Not Contrave, Qsymia, or Saxenda — those are not the step drugs on the current TRICARE form.
- Baseline weight: Documented starting weight, because annual renewal requires demonstrating at least 5% loss (adults) or 4% loss (ages 12-17).
At the appointment, ask your provider to:
- Submit the correct PA form (weight-management form for Wegovy/Zepbound, diabetes form for Ozempic/Mounjaro)
- Include medical necessity documentation if requesting non-formulary pricing
- Confirm the PA has been sent to Express Scripts and provide a reference number or timeline
- Document your baseline weight and any comorbidities in today's visit notes for future renewal
If you have sleep apnea (AHI ≥15) and want Zepbound: Ask whether the OSA pathway may be a better fit — the OSA path does not require the generic phentermine step-therapy trial.
If your teen (ages 12-17) needs coverage: Wegovy injection is the only GLP-1 listed on the current pediatric path. Pediatric renewal requires 4% baseline weight loss.
This checklist was assembled from current TRICARE.mil coverage guidance, the Express Scripts GLP-1 FAQ, the March 12, 2026 weight-loss PA form, and the TRICARE Prior Authorization Newsroom article. Sources verified .
What If TRICARE Denies Your GLP-1 Request?
A denial is not automatically the end. But the right next step depends on why it was denied.
Identify the Denial Type
Ask Express Scripts or your provider for the specific denial reason in writing. It will generally fall into one of three categories:
- Plan exclusion (TFL, direct care only, or another excluded plan) → Not fixable through appeals. See alternatives below.
- Missing documentation → A corrected PA resubmission is usually faster than a formal appeal.
- Wrong-path denial → Resubmit with the correct drug and diagnosis path.
File a Formal Pharmacy Appeal (If Needed)
If the denial seems wrong based on your documentation, or if a corrected PA was already denied, a formal pharmacy appeal is the next step. TRICARE’s official appeals instructions require:
- • A written appeal
- • Signed by you (the beneficiary)
- • Explains why you disagree with the denial
- • Includes a copy of the denial decision
- • Submitted within 90 days of the denial date — this is a hard deadline
Second-Level Review
If the first appeal is denied, TRICARE offers a second-level review. At this stage, having your provider participate in a peer-to-peer review — where they discuss medical necessity directly with a clinical reviewer — can be valuable. Ask your provider if they’re willing to request one.
Will TRICARE Cover Foundayo (Orforglipron)?
Foundayo — the first oral GLP-1 pill that can be taken at any time of day without food or water restrictions — received FDA approval on . It’s manufactured by Eli Lilly, the same company behind Zepbound and Mounjaro.
As of , we have not confirmed Foundayo on the TRICARE formulary.
The DoD Pharmacy & Therapeutics Committee reviews the formulary quarterly, so a decision could come in a future review cycle — but no public timeline has been announced.
Self-pay option: Eli Lilly offers Foundayo through LillyDirect at $149/month (0.8mg), $199/month (2.5mg), and $299/month (5.5mg+). Doses 14.5mg and 17.2mg have separate purchase-offer terms requiring refilling within 45 days.
Savings card: Lilly’s commercial savings card can reduce costs to as low as $25/month — but only for patients with commercial insurance that covers Foundayo. TRICARE beneficiaries are not eligible for the Foundayo commercial savings card — federal law prohibits manufacturer copay assistance for government insurance programs.
What to watch: Express Scripts formulary updates and DoD P&T Committee quarterly reviews.
What Are Your Options If TRICARE Won’t Cover You?
If you’ve confirmed your TRICARE plan excludes weight-loss medication coverage — or you’ve exhausted the PA and appeals process — you still have paths forward.
First: Make Sure You Haven’t Missed a Covered Path
- Are you on the wrong drug path? If you were denied for Ozempic, ask about Wegovy. If you were denied on the weight-loss pathway because of step therapy, check whether the Zepbound-for-OSA pathway applies.
- Do you have secondary commercial insurance? If your spouse has employer-sponsored insurance, that commercial plan may cover GLP-1s with its own PA process — and you can use manufacturer savings cards with commercial insurance.
- Are there covered non-GLP-1 options? Generic phentermine, Contrave, and other weight-loss medications may be covered under TRICARE Prime/Select with PA. They work differently than GLP-1s — and trying one of the listed generic agents also satisfies the step-therapy requirement if you later want Wegovy or Zepbound.
Cash-Pay Alternatives Outside of TRICARE
Disclosure: The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Links below are affiliate links — we may earn a commission if you sign up. This does not affect our coverage rules analysis, which is based entirely on official TRICARE, DHA, Express Scripts, and FDA sources.
Important: None of these providers submit prior authorizations to TRICARE or bill TRICARE for GLP-1 weight-loss medications. This is an out-of-pocket expense. Eden, MEDVi, and SHED offer compounded GLP-1 formulations prepared by licensed compounding pharmacies. Compounded medications are not FDA-approved and have not been independently evaluated by the FDA for safety, efficacy, or quality. Ro prescribes FDA-approved brand-name medications.
Eden
Trustpilot 4.4/5 · 3,300+ reviews · 100,000+ members · Flat pricing at every dose
Flat pricing with a price-lock guarantee — the cost doesn’t increase as your dose titrates up. For TFL beneficiaries who would otherwise pay $1,000+/month at retail, programs starting well below that represent a meaningful reduction even without insurance.
See Eden’s current pricing and lock in your rate →MEDVi
Trustpilot 4.4/5 · 11,400+ reviews · LegitScript certified · Largest independent review footprint
LegitScript certified, meaning their pharmacy practices have been independently verified. Largest verified public review footprint in the telehealth GLP-1 space we’ve found.
Check eligibility with MEDVi →Ro
FDA-approved brand-name Zepbound® and Foundayo™ · Starts at $39/month membership
Ro prescribes FDA-approved GLP-1 options including Zepbound and Foundayo through the Ro Body program. Membership starts at $39 for the first month, then $149/month (or as low as $74/month with an annual prepaid plan). Medication cost is separate from membership and varies by drug, dose, and your insurance situation. Ro does not coordinate GLP-1 coverage with TRICARE — this would be a self-pay path.
See Ro’s current program details and pricing →For a deeper comparison of these and other providers, see our full GLP-1 telehealth provider comparison →
What We Actually Verified for This Page
We built this guide by reviewing current official TRICARE, DHA, Express Scripts, and FDA source documents — not by summarizing other articles about TRICARE.
| Source | What We Checked | Date Verified | Status |
|---|---|---|---|
| Express Scripts TRICARE GLP-1 FAQ (militaryrx.express-scripts.com) | Drug-by-drug coverage rules, plan eligibility, pharmacy channels | ✅ Verified | |
| TRICARE.mil Wegovy/Ozempic/Mounjaro FAQ | Coverage requirements, PA and medical necessity forms | ✅ Verified | |
| DHA Newsroom coverage explainer (Aug 5, 2025) | Plan eligibility, clinical criteria, excluded beneficiary groups | ✅ Verified | |
| DHA Newsroom TFL Q&A (Sept 8, 2025) | TFL exclusion rationale, diabetes continuation, federal law basis | ✅ Verified | |
| DHA Prior Authorization Newsroom article | PA timeline, USFHP pharmacy plan status, prescriber requirements | ✅ Verified | |
| Weight-loss PA form via Formulary Search Tool | BMI criteria, comorbidity list, step therapy (generic phentermine class), lifestyle documentation, OSA path, pediatric path, renewal thresholds | ✅ Verified — form dated March 12, 2026 | |
| Express Scripts 2026 copay announcement + TRICARE.mil/Costs/PharmacyCosts | Copay amounts by pharmacy channel, formulary status, and beneficiary category | ✅ Verified — effective Jan 1, 2026 | |
| MOAA reporting (Sept 2025, Oct 2025, March 2026) | TFL coverage change, legal challenge, advocacy status | ✅ Verified | |
| Eli Lilly / Foundayo.lilly.com | FDA approval date, LillyDirect pricing tiers, savings card terms and exclusions | ✅ Verified |
What We Could Not Fully Verify
- Saxenda: Current live formulary tier and standalone PA form not confirmed from public-facing documents. Marked [NEEDS VERIFICATION].
- Wegovy tablets: Exact formulary classification for the oral form (approved Jan 2026) not confirmed separately from the injection.
- USFHP pharmacy coverage: Official DHA materials contradict each other on whether USFHP uses the TRICARE Pharmacy Program. We flagged this rather than guessing.
- Foundayo TRICARE formulary status: Not confirmed from public-facing documents as of April 15, 2026.
- Per-drug copay amounts: Confirm exact tier for each drug using the live Formulary Search Tool — updated quarterly.
Frequently Asked Questions
Does TRICARE cover GLP-1 for weight loss?
Yes, but only for TRICARE Prime, Select, and certain premium-based plans (Reserve Select, Young Adult, Retired Reserve, CHCBP, and related overseas variants). Wegovy, Zepbound, and Saxenda are the covered weight-loss GLP-1s. Prior authorization with step therapy is required — specifically, a 3-month trial of generic phentermine or another listed sympathomimetic agent, plus 6 months of documented lifestyle modification and BMI criteria. TRICARE For Life and direct-care-only beneficiaries are excluded from weight-loss GLP-1 coverage as of August 31, 2025.
Does TRICARE cover Wegovy?
Yes, for eligible plans with approved prior authorization and completed step therapy. Active-duty servicemembers pay $0. Other beneficiaries pay approximately $44 per 90-day supply via Home Delivery at the brand-name formulary rate — confirm the exact copay for your drug using the Formulary Search Tool. Not covered for TRICARE For Life beneficiaries for weight loss.
Does TRICARE cover Zepbound?
Yes, same eligibility and PA requirements as Wegovy for the weight-management path. Zepbound also has a distinct OSA (obstructive sleep apnea) prior authorization pathway — BMI ≥30 and AHI ≥15 — which does not require the step-therapy trial of generic phentermine. Not covered for TFL beneficiaries for weight management.
Does TRICARE cover Zepbound for sleep apnea?
Yes. The March 12, 2026 PA form includes a Zepbound-specific OSA path for adults 18+ with BMI ≥30 and AHI ≥15. This is separate from the weight-management path and does not require the generic phentermine step-therapy trial. Wegovy does not have an FDA-approved OSA indication and cannot use this route.
Does TRICARE cover Ozempic for weight loss?
No. Ozempic is covered by TRICARE only for type 2 diabetes. The diabetes PA form explicitly blocks coverage when Ozempic is prescribed for weight loss. If your goal is weight management, the correct drug to request is Wegovy — the same active ingredient but a different FDA approval and TRICARE coverage path.
Does TRICARE cover Mounjaro for weight loss?
No. Mounjaro is covered for type 2 diabetes only. For weight management, the correct request is Zepbound — same active ingredient as Mounjaro, but FDA-approved for weight management.
Does TRICARE For Life cover weight-loss GLP-1 medications?
No, not since August 31, 2025. The Defense Health Agency ended TFL coverage for weight-loss medications. GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza) remain covered for TFL with prior authorization. A legal challenge to this policy is pending as of April 2026, but no reversal is expected in the near term.
How long does TRICARE prior authorization take?
TRICARE's public guidance says the traditional PA process takes approximately 10 business days after Express Scripts receives the completed request. Actual timelines vary. If your provider needs to submit additional documentation or if the initial PA is denied and resubmitted, the process can take several weeks.
Can I appeal a TRICARE GLP-1 denial?
Yes. TRICARE pharmacy appeals must be written, signed by the beneficiary, explain why you disagree with the denial, include a copy of the denial decision, and be submitted within 90 days of the denial date. If a corrected PA resubmission can resolve the problem — fixing missing documentation or wrong-path issues — that is usually faster than a formal appeal.
Can a telehealth doctor submit TRICARE prior authorization?
Only if the telehealth provider is an MTF provider or a TRICARE-authorized network provider who has billed TRICARE for the assessment and/or treatment planning. Most commercial telehealth GLP-1 platforms operate outside the TRICARE network and cannot submit these PAs.
What if I have US Family Health Plan?
Do not assume the standard TRICARE coverage rules apply. Official DHA materials contradict each other on whether USFHP uses the TRICARE Pharmacy Program — one source groups it under Prime-eligible plans, while another says USFHP has its own separate pharmacy plan. Contact your USFHP site directly to confirm coverage.
What if my doctor says TRICARE will never approve it?
That statement is usually based on an incomplete understanding of the coverage rules. If your doctor is referring to Ozempic or Mounjaro for weight loss — yes, those specific drugs won't be approved for that purpose. But Wegovy and Zepbound have their own weight-management coverage path with specific, documented criteria. If you meet those criteria and your provider submits the correct form with the right step-therapy documentation, approval is achievable.
Not sure which GLP-1 program fits your situation?
Take our free 60-second matching quiz — we’ll match you to the right path based on your insurance type (TRICARE, Medicare, commercial, uninsured), your budget, and medication preference.
Take our free 60-second GLP-1 matching quiz →Check Ro eligibility — free, 2 minutes →Related guides
- GLP-1 copay assistance programs 2026 — every savings card, PAP, and Medicare Bridge option
- Blue Cross Wegovy prior authorization — what each plan actually requires
- Best Wegovy providers that accept insurance in 2026
- Best GLP-1 telehealth providers compared for 2026
- Cheapest GLP-1 options without insurance — full pricing breakdown
- GLP-1 providers that accept Blue Cross — full comparison
- Aetna Wegovy prior authorization checklist (2026)
This page is reviewed and updated monthly or whenever TRICARE, DHA, or Express Scripts publishes policy changes. Pricing and coverage details are subject to change — always confirm with your provider and the TRICARE Formulary Search Tool before making medical decisions. Published by The RX Index, a pricing intelligence and comparison resource for GLP-1 telehealth providers.